Insight, The Journal of ASORN ASORN Insight 2018 Q3 - Page 20

18 FOCUS Ophthalmic Issues in the Hematopoietic Stem Cell Transplant Recipient Continued from page 17 TABLE 2 Allogeneic HSCT Medications and Reported Ocular/Ophthalmic Effects Medication Purpose Ocular/ophthalmic effects Source Cyclosporine Immunosuppression Retinal toxic blindness (rare) López-Jiménez et al., 1997 Tacrolimus Immunosuppression Bilateral vision loss (rare) Apuri, Carlin, Bass, Nguyen, & Greene, 2014 (Not an ophthalmic effect: Tacrolimus can cause posterior reversible encephalopathy, a neurological syndrome that may cause reversible vision changes including total vision loss.) Voriconazole Antifungal Loss of visual acuity Walsh et al., 2002 Visual hallucinations Eiden et al., 2007 Reversible vision disturbances Corticosteroids Treatment of GVHD Cataracts Nassar, Tabbara & Aljurf, 2013 Increased intraocular pressure Central serous retinopathy Busulfan Conditioning Cataracts (rare) Al-Tweigeri, Nabholtz, & Mackey, 1996 Cyclophosphamide (Cytoxan) Conditioning Dry eye (keratoconjunctivitis sicca) Klein & Burns, 2008 Conjunctivitis Klein & Burns, 2008 Blurred vision Fludarabine Conditioning Al-Tweigeri, Nabholtz, & Mackey, 1996 Visual changes Ding et al., 2008 Visual field deficits Photophobia Hallucinations Complete loss of vision Radiation (TBI) Conditioning Cataracts Al-Tweigeri, Nabholtz, & Mackey, 1996 Retinopathy Methotrexate During and after transplant for prevention and treatment of GVHD, especially steroid-refractory Conjunctivitis Huang, 2005 Increased lacrimation Giaccone, 2005 Blurred vision Klein & Burns, 2008 Photophobia Ocular pain Note: TBI = total body irradiation; GVHD = graft-vs.-host disease. A current medication history is extremely i 'FB2vV7BG&7B6R&"FFVF6F2BF6W045BFVG2&RVFRVF6F26VFrV6vRg&WVVFǒ6VRF&R"f"FW67&Fb67W&W76fW2F&F72Ff&2BFgVv2f"F2VF6F2W6VBvVV245BvFFV"&W'FVB7V"V'2"6R66W2W&VFǒ'F7V&ǒFRV&ǒF֖2VffV7G24$4tB7VW"#